TY - JOUR
T1 - Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health
AU - De Villiers, Tobie
AU - Pines, Amos
AU - Panay, Nick
AU - Gambacciani, Marco M
AU - Archer, David F
AU - Baber, Rodney
AU - Davis, Susan Ruth
AU - Gompel, Anne
AU - Henderson, Victor W
AU - Langer, Robert
AU - Lobo, Rogerio A
AU - Plu-Bureau, Genevieve
AU - Sturdee, David W
PY - 2013
Y1 - 2013
N2 - Ten years after the first results from the Women s Health Initiative
(WHI) trial were published, it seems that the atmosphere
around the issue of menopausal hormone therapy
(MHT) is increasingly evidence-based and more rational. The
pendulum has swung back from its peak negative sentiment,
primarily as a result of acknowledging the importance of the
age at initiation and the good safety profi le of MHT in women
younger than 60 years. In November 2012, the International
Menopause Society (IMS) organized a workshop with the participation
of representatives from The American Society for
Reproductive Medicine, The Asia Pacifi c Menopause Federation,
The Endocrine Society, The European Menopause and
Andropause Society, The International Osteoporosis Foundation,
The North American Menopause Society and other
related medical associations, with the aim of reaching a global
consensus on the use of MHT and updating the 2011 IMS
recommendations. The Global Consensus Statement emerging
from this meeting was recently published simultaneously in
Climacteric and Maturitas and was endorsed by the above
societies in addition to the IMS.
The 2013 update of the IMS Recommendations is similar
in structure and principle to the 2011 version but with additional
clinical data where needed. Throughout the Recommendations,
the term MHT has been used to cover therapies including estrogens, progestogens and combined therapies.
The IMS is aware of the geographical variations related to
different priorities of medical care, different prevalence of diseases,
and country-specifi c attitudes of the public, the medical
community and health authorities toward menopause management,
different availability and licensing of products, all
of which may impact on MHT. These Recommendations and
the subsequent key messages therefore give a simple overview
that serves as a common platform on issues related to the
various aspects of hormone therapy, which could be easily
adap
AB - Ten years after the first results from the Women s Health Initiative
(WHI) trial were published, it seems that the atmosphere
around the issue of menopausal hormone therapy
(MHT) is increasingly evidence-based and more rational. The
pendulum has swung back from its peak negative sentiment,
primarily as a result of acknowledging the importance of the
age at initiation and the good safety profi le of MHT in women
younger than 60 years. In November 2012, the International
Menopause Society (IMS) organized a workshop with the participation
of representatives from The American Society for
Reproductive Medicine, The Asia Pacifi c Menopause Federation,
The Endocrine Society, The European Menopause and
Andropause Society, The International Osteoporosis Foundation,
The North American Menopause Society and other
related medical associations, with the aim of reaching a global
consensus on the use of MHT and updating the 2011 IMS
recommendations. The Global Consensus Statement emerging
from this meeting was recently published simultaneously in
Climacteric and Maturitas and was endorsed by the above
societies in addition to the IMS.
The 2013 update of the IMS Recommendations is similar
in structure and principle to the 2011 version but with additional
clinical data where needed. Throughout the Recommendations,
the term MHT has been used to cover therapies including estrogens, progestogens and combined therapies.
The IMS is aware of the geographical variations related to
different priorities of medical care, different prevalence of diseases,
and country-specifi c attitudes of the public, the medical
community and health authorities toward menopause management,
different availability and licensing of products, all
of which may impact on MHT. These Recommendations and
the subsequent key messages therefore give a simple overview
that serves as a common platform on issues related to the
various aspects of hormone therapy, which could be easily
adap
UR - http://informahealthcare.com/doi/pdf/10.3109/13697137.2013.795683
U2 - 10.3109/13697137.2013.795683
DO - 10.3109/13697137.2013.795683
M3 - Article
SN - 1369-7137
VL - 16
SP - 316
EP - 337
JO - Climacteric
JF - Climacteric
IS - 3
ER -